Thyrocare
Tests you can trust

September 01, 2026

To,

National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Sub: Communication received from API Holdings Limited regarding approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited

Ref: Scheme of Amalgamation of Docon Technologies Private Limited (“Transferor Company”), API Holdings Limited (“Transferee Company”) and their respective Shareholders under the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

Dear Sir/Madam,

We wish to inform you that Docon Technologies Private Limited ("Docon" or the "Transferor Company") and API Holdings Limited ("API" or the "Transferee Company") had filed a Scheme of Amalgamation of Docon with API, along with their respective shareholders ("the Scheme"), before the Hon'ble National Company Law Tribunal, Mumbai Bench ("NCLT"), under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

We are pleased to inform you that the Hon'ble NCLT, Mumbai Bench, vide its order pronounced on August 31, 2026, has sanctioned the aforesaid Scheme of Amalgamation. A copy of the said Order is available on the website of the Hon'ble NCLT at https://nclt.gov.in/.

As per the Scheme, the Scheme shall become operative upon the "Effective Date", which is the date when all conditions precedent, including filing of the certified copy of the NCLT Order with the Registrar of Companies (“RoC”) in Form No. INC-28, are completed or duly waived. Docon and API shall file the certified copy of the NCLT Order with the RoC within the prescribed timelines.

Upon the Scheme becoming effective, Docon shall stand amalgamated with API, and all assets, liabilities, undertakings, rights and obligations of Docon shall stand transferred to and vested in API in accordance with the provisions of the Scheme. Consequently, Docon’s entire shareholding in the Company, comprising 8,12,00,000 equity shares, representing 51.02% of the paid-up share capital of the Company, shall, by operation of law, stand transmitted and vested to API on the Effective Date.

It is further clarified that Docon is a wholly owned subsidiary of API. Both, Docon and API are presently members of the Promoter Group of the Company. Upon the transmission and vesting of Docon’s shareholding in the Company to API on the Effective Date, there shall be no change in the aggregate shareholding of the Promoter and Promoter Group of the Company, which shall continue to be 51.02%. The said shareholding shall be held by API, being a member of the Promoter Group, post the Effective Date, in place of Docon.

Thyrocare
Tests you can trust

The shareholding pattern before and after implementation of the Scheme is set out in the table below:

		Before Scheme Implementation		After Scheme implementation	
S. No	**Category of Shareholders**	**No of Shares**	**%of holding**	**No of Shares**	**%of holding**
A)	**Promoter & Promoter Group**				
1	Docon Technologies Private Limited	8,12,00,000	51.02%	Nil	Nil
2	API Holdings Limited	Nil	Nil	8,12,00,000	51.02%
B)	**Public Shareholders**	7,79,65,315	48.98%	7,79,65,315	48.98%
	Total (A+B)	**15,91,65,315**	**100.00%**	**15,91,65,315**	**100.00%**

The Company is submitting this intimation to the Stock Exchanges for information and records.

Yours Faithfully,
For **Thyrocare Technologies Limited,**

Brijesh Kumar
Digitally signed by Brijesh Kumar
Date: 2026.09.01 17:20:15 +05'30'

Thyrocare Technologies Limited

Brijesh Kumar
Company Secretary and Compliance Officer